Structure Encountered

Synklino

Develops fusion protein therapies to eliminate cytomegalovirus in transplant recipients

Synklino's SYN002 entered Phase 1, clearing latent CMV from donor kidneys before transplant.

SIGNAL·Phase 1 first patient dosed·First patient dosed·SCORE 74·02 JUN 2026 · 11:54 UTC

● CAPTURE — IMAGE INCOMINGFRAME 01 / 01

STRUCT. / SYNKLINO

/ Copenhagen, Denmark

CAPT. / 02.06.26 11:54:29Z

SIGNAL / 74 / 100

Image relayed by The Biotech Voyager during pass over structure Synklino. Resolution as transmitted.

001Vital Statistics

DATA LOCKED

Designation

Synklino

Coordinates

Copenhagen, Denmark

Stage

Phase1

Type

Therapeutics

Modalities

protein therapeutic

Therapeutic area

Infectious Disease

002Signature Detected

EVENT DETECTED

Event type

Phase 1 first patient dosed

Magnitude

First patient dosed

Lead

Prof. Atul Humar (Ajmera Transplant Centre, Toronto)

Participating

Investigator-sponsored Phase 1; 6-month post-transplant CMV monitoring

003Architecture

PLATFORM PROFILE

Target class

US28, a CMV-encoded GPCR displayed on both latent and lytic infected cells. SYN002 is a chemokine-based immunotoxin fusion protein that finds those cells and kills them, including the latent reservoir antivirals miss.

Differentiator

Letermovir and maribavir suppress active CMV but leave the latent reservoir, so reactivation stays a transplant threat. SYN002 is perfused through the donor kidney before transplant to clear that reservoir, cutting reactivation over 90% preclinically.

Lead asset

SYN002 (US28 chemokine immunotoxin), Phase 1

Pipeline depth

1 lead (SYN002, CMV in kidney transplant); ex vivo and in vivo administration routes

004Voyager Assessment

MACHINE-GENERATED

CMV is the infection that haunts transplant medicine. Antivirals like letermovir keep it quiet, but they can't clear the latent virus hiding in infected cells, so it waits and reactivates. Synklino's idea is to go after the reservoir directly, and to do it before the organ is even in the patient. SYN002 is a fusion protein that recognizes US28, a viral receptor on latently infected cells, and kills them. They perfuse it through the donor kidney during prep. Preclinically that cut reactivation over 90%. It's a first patient, with six months of monitoring ahead, so watch the reactivation rate.

005Adjacent Structures

FRONTIER MAP

Merck· letermovir, CMV prophylaxisTakeda· maribavir, CMVAiCuris· CMV antiviralsModerna· mRNA CMV vaccineTransMedics· ex vivo organ perfusioneGenesis· engineered donor organs

— End of transmission —This signal was received and processed by The Biotech Voyager and HOUSTON. Transmissions are auto-generated from public sources and platform telemetry. They are not edited for prose. For human analysis and connection to other signals, watch the Tuesday or Thursday mission broadcast aboard the [SHIP]. Field notes — long-form synthesis from the crew — are archived separately.